卡培他滨联合奥沙利铂、 多西他赛一线治疗晚期胃癌临床观察

    Capecitabine combined with oxaliplatin and docetaxel in treatment of advanced gastric cancer

    • 摘要: 目的:观察卡培他滨联合奥沙利铂、多西他赛一线治疗晚期胃癌的疗效和安全性。方法:选择经病理证实的晚期胃癌患者26例,卡培他滨2 000 mgm-2 d-1,分早晚口服,d1~14;奥沙利铂130 mg/m-2,静脉滴注,持续2 h以上,d1;多西他赛60 mg/m2,静脉滴注,d1,21 d为1个周期。结果:完全缓解2例,部分缓解12例,稳定8例,进展4例,总有效率53.8%,1年生存率45.1%,中位肿瘤进展时间6个月,中位生存期11个月。不良反应主要有骨髓抑制、恶心、呕吐、神经毒性和腹泻。结论:卡培他滨联合奥沙利铂、多西他赛一线治疗晚期胃癌安全、有效、依从性好,值得临床推广。

       

      Abstract: Objective:To observe the efficacy and safety of capecitabine combined with oxaliplatin and docetaxel(DOX regimen)in treatment of advanced gastric cancer.Methods:A total of 26 patients with advanced gastric cancer confirmed by pathology were included in this study.All the patients were given oral administration of capecitabine 2 000 mg/m2 two times a day;on d1-14,oxaliplatin 130 mg/m2 and docetaxel 60 mg/m2 were given intravenously for more than 2 hours each time.The regimen was repeated every 21 days.Results:Complete response was observed in 2 cases,partial response in 12,stable in 8 and progression in 4.The total effective rate was 53.8%;the median time to progression was 6 months and the median overall survival was 11 months.The main side effects were bone marrow suppression,nausea,vomiting,neurotoxicity and diarrhea.Conclusions:DOX is an effective,safe and well tolerated chemotherapy regimen for patients with advanced gastric cancer.It is worthy of clinical popularization.

       

    /

    返回文章
    返回